Drug Profile
DNL 747
Alternative Names: DNL747; SAR 443060Latest Information Update: 23 Sep 2022
Price :
$50
*
At a glance
- Originator Harvard University
- Developer Denali Therapeutics Inc; Sanofi
- Class Antidementias; Small molecules
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis
Most Recent Events
- 23 Sep 2022 Discontinued - Phase-I for Alzheimer's disease (In volunteers) in Netherlands (PO) (Denali Therapeutics pipeline, September 2022)
- 23 Sep 2022 Discontinued - Phase-I for Amyotrophic lateral sclerosis (Treatment-experienced) in Netherlands (PO) (Denali Therapeutics pipeline, September 2022)
- 23 Sep 2022 Discontinued - Phase-I for Amyotrophic lateral sclerosis (Treatment-experienced) in USA (PO) (Denali Therapeutics pipeline, September 2022)